Drug Repositioning Examples
Metformin in combination with Rifampicin
The NCATS OpenData COVID-19 portal is a resource designed to rapidly and openly share SARS-CoV-2 screening data and assay information with the global health community. In addition to screening data, the site also hosts a rich database of therapeutic activity data reported against SARS-CoV-2 variants, as well as information about common SARS-CoV-2 animal models.
A 3-center Phase 2b clinical trial of metformin, a generic diabetes drug, as an adjunct therapy for tuberculosis. Open IP, open data (once ready), and openly-available protocol published in open access academic journal. In partnership with the Government of India’s National Institute for Research in Tuberculosis (NIRT).
The "TB, Chikungunya and Nipah Virus Knowledge Graph" is an open, living, AI-powered, automatically updated knowledge base and knowledge graph focused on the specific content needed to enable drug discovery.
Databases and IT resources
The NCATS OpenData COVID-19 portal is a resource designed to rapidly and openly share SARS-CoV-2 screening data and assay information with the global health community. In addition to screening data, the site also hosts a rich database of therapeutic activity data reported against SARS-CoV-2 variants, as well as information about common SARS-CoV-2 animal models.
NCATS Pharmaceutical Collection (NPC) for drug repurposing
The NCATS Pharmaceutical Collection is a comprehensive, publicly accessible collection of approved molecular entities for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of diseases and interventions.
NCATS-CTSA Clinical data portal on COVID-19
NCATS-CTSA Clinical data portal on COVID-19 that contains patient data on clinical and laboratory diagnostic data from hospitals and healthcare plans. Can be used for repurposing and pre-clinical development efforts.
Project Mentoring and Support
Project mentoring (in collaboration with the EJPRD programme)
Advancing promising technologies and therapies towards clinical application is a complex undertaking. Academic research often lacks easy access to regulatory, therapy development expertise, manufacturing, and healthcare practice, leading to high failure rates. For this reason, the European Joint Programme on Rare Diseases (EJP RD) has initiated a mentoring programme for rare disease researchers.
The COVID-19 Fast Response Service is a coordinated and accelerated procedure for researchers to access the academic facilities, services and resources of the three medical research infrastructures: the European Research Infrastructure for Translational Medicine (EATRIS), the European Clinical Research Infrastructure network (ECRIN) and the European research infrastructure for biobanking (BBMRI), working together under the umbrella of the Alliance of Medical Research Infrastructures (EU-AMRI).
EATRIS offers a range of services to help researchers develop a robust translational research plan and form a world class research consortium. The services listed here can be provided for any funding call supporting translational research, including but not limited to Horizon Europe (e.g. Health cluster, European Innovation Council, Marie Skłodowska Curie), the Innovative Health Initiative, ERA-NETs, European Joint Programmes and European Partnerships as well as calls published by national funders and charities.
Regulatory Advice and Health Economics Support
Access to regulatory expertise
Access to regulatory expertise such as ODD application support.
View EATRIS Regulatory Services >
(Early) Health Technology Assessment
A 3-center Phase 2b clinical trial of metformin, a generic diabetes drug, as an adjunct therapy for tuberculosis. Open IP, open data (once ready), and openly-available protocol published in open access academic journal. In partnership with the Government of India’s National Institute for Research in Tuberculosis (NIRT).
Find out more about the EATRIS Health Technology Assessment service here >
